Sign in with your email address username.


[Correspondence] Bivalirudin versus heparin use for patients undergoing PPCI

Although randomised clinical trials are the gold standard used to define treatment recommendations, beneficial effects of a drug for treatment might be obscured because of the effect of adjunctive treatment on patient outcomes. The GUSTO trial investigators1 reported that treatment of ST-segment elevation myocardial infarction (STEMI) with tissue plasminogen activator reduced mortality compared with the use of streptokinase. To show this benefit, effective adjunctive treatment with intravenous heparin was necessary.